RNS Number : 3381T
Cathay International Holdings Ld
19 November 2013

Cathay International Holdings Limited
("Cathay" or the "Company")
Interim Management Statement Hong Kong, 19 November 2013 - Cathay International Holdings Ltd. (LSE:CTI.L), an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China ("PRC"), today announces its Interim Management Statement for the period from 1 July 2013 to 19 November 2013 in accordance with FSA Disclosure and Transparency Rule 4.3. Mr. Lee Jin-Yi, CEO of Cathay International Holdings Limited, commented: "Cathay remains focused on creating synergies across the Group and on expanding its product portfolio in key areas. We are pleased with inositol's recent progress and will continue to advance and develop this programme. We remain positive about the opportunities within the growing Chinese pharmaceutical and healthcare market and for the potential for inositol." Business UpdateDuring the period, Lansen continued its focus on marketing and growing the sales of Pafulin, Tuoshu and Mycophenolate Mofetil (MMF) in the rheumatology markets and has also started to widen the indications of Pafulin in dermatology. The new business development team at Lansen is actively reviewing a list of drug opportunities for the treatment of autoimmune related diseases to expand its current product portfolio. During the last quarter, Lansen entered into a plant extract supply agreement with Haotian, continuing its strategy to develop its plant extract business into a medical grade supplier of key ingredients for healthcare products, and successfully secured a reliable supply of good quality plant extract ingredients at a competitive price for itsproduction needs. Lansen has also acquired the misoprostol development project from Tianjin Longbai, which represents an opportunity to invest in the labor induction market and adds to its gynaecological product portfolio. The Company believes that Lansen's transactions with Haotian and Tianjin Longbai will create business synergies within the Group.As reported in the first half, Haotian began working with corn fluid suppliers to ensure the smooth and continued supply of raw materials. In the last quarter, Haotian has continued to work on improving corn fluid flow and is now starting to implement the improved process. This, along with the usual low levels of phytin that can be extracted from corn fluid during new corn harvest season, has affected our phytin yield and supply. Therefore, we have adjusted our target inositol production run rate to 1200 tonnes per annum by the end of this year.

To continue reading this noodl, please get the original version here.

distributed by